Table 1.

Adjuvant Therapy FDA Approval and Indications

Drug Name	FDA Approval	Indication	Trial Leading to Approval	Dosing Regimen
High-dose IFNα	1996	High-risk resected melanoma	ECOG 1684	Initiation: 20 million IU/m2 for 4 weeks Maintenance: 10 million IU/m2 for 11 months
Ipilimumab	2015	Resected stage III melanoma	EORTC 18071	3 mg/kg Q2W for up to 2 years
Nivolumab	2017	Resected stage III or IV melanoma	Checkmate-238	3 mg/kg Q2W for 4 doses, then 3 mg/kg Q2W for up to 2 years
Dabrafenib + trametinib	2018	Resected stage III melanoma with BRAF V600 mutations	COMBI-AD	350 mg PO daily + 2 mg PO daily until disease progression
Pembrolizumab	2019	Resected stage III melanoma	EORTC 1325	2 mg/kg Q3W for up to 2 years
Vemurafenib	Unknown status	Stages IIC-IIIB resected melanoma	BRIM8	960 mg BID until disease progression or unacceptable toxicity